The efficacy of risk model scores to predict venous thromboembolism (VTE) in ambulatory cancer patients is under investigation, aiming to stratify on an individual risk basis the subset of the cancer population that could mostly benefit from primary thromboprophylaxis.
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study / Cella, Chiara Alessandra; Di Minno, Giovanni; Carlomagno, Chiara; Arcopinto, Michele; Cerbone, Anna Maria; Matano, Elide; Tufano, Antonella; Lordick, Florian; De Simone, Biagio; Muehlberg, Katja Sibylle; Bruzzese, Dario; Attademo, Laura; Arturo, Claudia; Sodano, Marta; Moretto, Roberto; La Fata, Ersilia; De Placido, Sabino. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 22:5(2017), pp. 601-608. [10.1634/theoncologist.2016-0246]
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study
Cella, Chiara Alessandra;Di Minno, Giovanni;Carlomagno, Chiara;Arcopinto, Michele;Cerbone, Anna Maria;Matano, Elide;Tufano, Antonella;De Simone, Biagio;Bruzzese, Dario;Attademo, Laura;Arturo, Claudia;Sodano, Marta;Moretto, Roberto;La Fata, Ersilia;De Placido, Sabino
2017
Abstract
The efficacy of risk model scores to predict venous thromboembolism (VTE) in ambulatory cancer patients is under investigation, aiming to stratify on an individual risk basis the subset of the cancer population that could mostly benefit from primary thromboprophylaxis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Preventing Venous Thromboembolism in Ambulatory Cancer Patients- The ONKOTEV study.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
299.78 kB
Formato
Adobe PDF
|
299.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
